Home / News

News

PetVivo Holdings, Inc. to exhibit at the American Association of Equine Practitioners Virtual Convention and Trade Show

PetVivo Holdings, Inc. to exhibit at the American Association of Equine Practitioners Virtual Convention and Trade Show

MINNEAPOLIS, Dec. 07, 2020 (GLOBE NEWSWIRE) -- OTCQB: (PETV) PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company operating in the $19B veterinary market announced today it will be exhibiting at the American Association of Equine Practitioners (“AAEP”) Virtual Convention and Trade Show from December 5th to December 8th, 2020 that can be accessed online at https://convention.aaep.org/.

PetVivo is excited to meet with many of the more than 1,000 participants to talk about and introduce its lead product, KUSH®, a medical device injection of sterilized, hydrogel microparticles that are wet, slippery and spongy used in the treatment of lameness and other joint related afflictions, such as osteoarthritis. AAEP is the largest veterinary equine conference in the United States and plays host to many of the top industry professionals. As a highlight to the conference, PetVivo is hosting a presentation about joint afflictions and therapeutic treatments, which includes information about its own cartilage mimicking medical device, KUSH®. The presentation will feature a keynote speaker and expert in equine health, Tracy Turner, DVM, MS, Dipl. ACVS, Dipl. ACVSMR, who will provide beneficial insight on common lameness afflictions found in horses and the therapies he has used to treat such injured animals.

“I am incredibly excited to participate in the presentation hosted by PetVivo entitled “Kush® - a Promising New Treatment for Joint Problems” to share my thoughts and insights regarding equine lameness and the beneficial treatments for such afflictions,” explained Dr. Tracy Turner.

Conference Details:

American Association of Equine Practitioners Virtual Convention and Trade Show

Dates:

Sunday, December 6, 2020 9:00am – 5:00pm

Monday, December 7, 2020 9:00am – 5:00pm

Tuesday, December 8, 2020 9:00am – 4:00pm

Location: Virtual

For more information about PetVivo, Inc. and Kush, please contact info1@petvivo.com or visit https://petvivo.com/

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of eighteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product Kush, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.

CONTACT:

John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com 
(952) 405-6216

 

Forward-Looking commercial Statements:

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. These statements may be preceded by, followed by, or include the words “aim,” “anticipate,” “believe,” “estimate, “expect,” “forecast,” “intend,” “likely,” “outlook,” “plan,” “potential,” “project,” “projection,” “seek,” “can,” “could,” “may,” “should,” “would,” “will,” the negatives thereof and other words and terms of similar meanings. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. There is no assurance that any forward-looking statements will materialize. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

PetVivo Holdings, Inc. Announces Sponsored Research Agreement with Colorado State University for Osteoarthritis Treatment Study.

PetVivo Holdings, Inc. Announces Sponsored Research Agreement with Colorado State University for Osteoarthritis Treatment Study.

MINNEAPOLIS, Nov. 12, 2020 (GLOBE NEWSWIRE) -- OTCQB: (PETV) PetVivo Holdings, Inc. (OTCQB: PETV) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce the entry into a sponsored research agreement with Colorado State University (“CSU”) College of Veterinary Medicine and Biomedical Sciences to engage in a clinical study involving the treatment of osteoarthritis in canines through the administration of PetVivo’s proprietary medical device, KUSH®.

The treatment of osteoarthritis in canines through the administration of PetVivo’s proprietary medical device, KUSH®.

Felix Duerr, DVM, associate professor of small animal orthopedics, will serve as Principal Investigator for the research project. Dr. Duerr established and now oversees CSU’s Orthopedic Medicine and Mobility program. His clinical interests include sports medicine and rehabilitation, and minimally invasive surgery, including arthroscopy.

“The study designed by the team is novel and he hopes the research will lead to new ways to treat osteoarthritis, which affects up to 20% of all dogs, no matter the age,” said Dr. Duerr.

KUSH is a medical device that is administered by intraarticular injection in afflicted joints of animals, such as dogs and horses, for the treatment of osteoarthritis. The product is intended to provide a lubricious cushion between the bones to reinforce cartilage. A primary objective of PetVivo is to commercialize beneficial medical device products, such as KUSH, to further enhance the lives and happiness of companion animals and their owners.

About PetVivo Holdings, Inc.

For more information about PetVivo and Kush, please contact info1@petvivo.com or visit https://petvivo.com/

PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of eighteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product Kush, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.

CONTACT:

John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
5251 Edina Industrial Blvd.
Minneapolis, MN 55439
www.petvivo.com

Forward-Looking commercial Statements:

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. These statements may be preceded by, followed by, or include the words “aim,” “anticipate,” “believe,” “estimate, “expect,” “forecast,” “intend,” “likely,” “outlook,” “plan,” “potential,” “project,” “projection,” “seek,” “can,” “could,” “may,” “should,” “would,” “will,” the negatives thereof and other words and terms of similar meanings. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. There is no assurance that any forward-looking statements will materialize. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

nScrypt Bioprints PetVivo® Biomaterial for Orthopedic Implants

nScrypt Bioprints PetVivo® Biomaterial for Orthopedic Implants

Orlando, Florida, Oct. 20, 2020 (GLOBE NEWSWIRE) -- nScrypt is excited to announce the successful bioprinting of PetVivo® Holdings’ biomaterial, using nScrypt’s 3D Bio-Fabrication Tool (BAT).

The nScrypt BAT technology was able to easily 3D bioprint PetVivo’s proprietary aqueous hydrogel biomaterial in symmetrical structures. nScrypt’s BAT system uses five print heads in an ISO 5 cleanroom printing environment to create medical implants in a hospital setting.

Bioprinting PetVivo biomaterial with nScrypt’s BAT technologyAccording to nScrypt’s CEO, Dr. Ken Church:

We are delighted with the results of our BAT bioprinting of PetVivo’s biomaterial. Our BAT system outfitted with our SmartPumpTM and nFD tool heads precisely microdispenses or extrudes all the ingredients needed to construct living tissue, such as biomaterials, living cells, and scaffolds, with cell viability in excess of 95%. Our BAT uses the same technology as our 3D manufacturing systems, which can make surgical tools and devices for patients with healing challenges.

The PetVivo biomaterial, which consists of collagen, elastin, and heparin, can be used to create regenerative and/or biologically integrative medical devices, injected particles, coatings, and drug delivery vehicles. In addition, the PetVivo biomaterial can be combined with other biomaterials, enabling various kinds of implants to be created. PetVivo’s biomaterial technology is highly suited for the substitution or replacement of slower healing permanent implants used today, especially in orthopedic markets, such as spine and knee. PetVivo’s current product, Kush®, is being sold as an injected medical device particulate to reinforce damaged joint cartilage tissue in lame osteoarthritic dogs and horses by mimicking cartilage components, structure and function.

nScript is working in collaboration with PetVivo to ascertain a technological potential for creating on-demand medical devices in a hospital setting and to recreate biological structures to optimize the healing process. The PetVivo biomaterial mimics the living body’s extracellular matrix that all cells use as support to create tissue. Being able to print the PetVivo biomaterial in combination with other materials in a surgical setting can provide great medical benefit by helping to promote neovascularization, stem cell organization, and overall recruitment of tissue healing cells to mend the body. “We are all very excited to continue developing the PetVivo biomaterial with nScrypt’s 3D bioprinting capabilities and using with other biomaterials to make them more biologically integrative,” stated Dr. Church.

 

About nScrypt

Orlando, Florida-based nScrypt designs and manufactures award-winning, next-generation, high-precision microdispensing, 3D Manufacturing, and biomanufacturing equipment and solutions for industrial applications, with unmatched accuracy and flexibility. Serving the printed electronics, electronics packaging, solar cell metallization, communications, printed antenna, life science, chemical/pharmaceutical, defense, space, 3D printing, and bioprinting industries, our equipment and solutions are widely used by the military, academic and research institutes, government agencies and national labs, and private companies. The nScrypt BAT Series Bioprinter, which won the 2003 R&D 100 award, launched to the International Space Station in July 2019. www.nScrypt.com.

 

About PetVivo Holdings, Inc.

For more information about PetVivo and Kush, please contact info1@petvivo.com or visit https://petvivo.com/

PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of eighteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product Kush, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.

 

CONTACT:
Brandon Dickerson
nScrypt Inc.
Email: bdickerson2@nscrypt.com
Phone: (407) 275-4720

 

Attachment